Frederic Hammel
Director/Board Member bei Fabentech SAS
Profil
Frederic Hammel is currently an Independent Director at Fabentech SAS.
He is also a Venture Partner at Elaia Partners SAS and a Member-Supervisory Board at Nosopharm SAS.
Previously, he served as the Chairman & Chief Executive Officer at Sangamo Therapeutics France SAS, Director General at ETHERA SA, and General Manager at HealthCare Medical Technologies, Inc. He also briefly held the position of Chief Operating Officer at Génomic Vision SA. Mr. Hammel has a graduate degree from the University of Geneva, a graduate degree and an MBA from École Normale Supérieure, and an undergraduate degree from the University of Reims Champagne-Ardenne.
Aktive Positionen von Frederic Hammel
Unternehmen | Position | Beginn |
---|---|---|
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | Director/Board Member | - |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | Private Equity Investor | 18.12.2019 |
Nosopharm SAS
Nosopharm SAS Pharmaceuticals: MajorHealth Technology Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France. | Director/Board Member | - |
Ehemalige bekannte Positionen von Frederic Hammel
Unternehmen | Position | Ende |
---|---|---|
GENOMIC VISION | Chief Operating Officer | 01.04.2023 |
HealthCare Medical Technologies, Inc.
HealthCare Medical Technologies, Inc. Other Consumer ServicesConsumer Services HealthCare Medical Technologies, Inc. provides healthcare management services to health plans focused on obesity, diabetes, renal failure, heart disease, and high risk obstetrics. The company is headquartered in Sioux Falls, SD. | Corporate Officer/Principal | - |
ETHERA SA
ETHERA SA Medical SpecialtiesHealth Technology ETHERA SA provides diagnostic kits for indoor air pollution. It also develops solutions for measurement of chemical pollutants in the indoor air, especially for toxic volatile organic compounds. The firm's products include Profil'air modules, Profil'air sensors and Profil'air accessories. The company was founded by Yves Bigay, Thu-Hoa Tran-Thi and Sylvain Colomb in 2010 and is headquartered in Crolles, France. | Chief Executive Officer | - |
TXCELL | President | - |
Ausbildung von Frederic Hammel
University of Geneva | Graduate Degree |
École Normale Supérieure | Graduate Degree |
University of Reims Champagne-Ardenne | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GENOMIC VISION | Health Technology |
Private Unternehmen | 6 |
---|---|
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | Finance |
HealthCare Medical Technologies, Inc.
HealthCare Medical Technologies, Inc. Other Consumer ServicesConsumer Services HealthCare Medical Technologies, Inc. provides healthcare management services to health plans focused on obesity, diabetes, renal failure, heart disease, and high risk obstetrics. The company is headquartered in Sioux Falls, SD. | Consumer Services |
Sangamo Therapeutics France SAS
Sangamo Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics France SAS is a biotechnology company, which engages in developing platforms for T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases. The company was founded on April 12, 2001, and is headquartered in Valbonne-Sophia Antipolis, France. | Commercial Services |
ETHERA SA
ETHERA SA Medical SpecialtiesHealth Technology ETHERA SA provides diagnostic kits for indoor air pollution. It also develops solutions for measurement of chemical pollutants in the indoor air, especially for toxic volatile organic compounds. The firm's products include Profil'air modules, Profil'air sensors and Profil'air accessories. The company was founded by Yves Bigay, Thu-Hoa Tran-Thi and Sylvain Colomb in 2010 and is headquartered in Crolles, France. | Health Technology |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | Health Services |
Nosopharm SAS
Nosopharm SAS Pharmaceuticals: MajorHealth Technology Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France. | Health Technology |